PDF(Pubmed)
Abstract：
Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have shown relevant clinical efficacy in the management of psoriatic lesions in difficult-to-treat areas. In post hoc analysis of phase III trials in plaque psoriasis, bimekizumab has shown safety and complete clearance of high-impact areas. However, these studies did not focus on the effect of bimekizumab on facial lesions. Therefore, this case series represents the first clinical real-life experience of rapid and successful management of facial psoriasis with bimekizumab in six patients.
摘要：
牛皮癣是一种慢性炎症性疾病，可以影响身体的任何部位，但是，当它出现在某些地区时，像脸,它会产生非常重大的心理影响。生物制品,特别是IL-17和IL-23药物抑制剂，在难以治疗的领域中，已显示出相关的临床疗效。在斑块状银屑病III期试验的事后分析中，bimekizumab已显示出安全性和高影响区域的完全清除。然而,这些研究并不关注bimekizumab对面部病变的影响.因此,本病例系列代表了6例患者中首次使用比美珠单抗快速成功治疗面部银屑病的临床真实经验.
